Cocrystal Pharma, Inc. Common Stock COCP
$1.11
-3.48%
at last close
Analyst Consensus
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2025-06-20 | HC Wainwright & Co.Raghuram Selvaraju |
Maintains | Buy | $7 → $6 |
| 2025-01-22 | HC Wainwright & Co.Raghuram Selvaraju |
Reiterates | Buy | $7 |
| 2024-08-22 | HC Wainwright & Co.Raghuram Selvaraju |
Maintains | Buy | $10 → $7 |
| 2024-05-14 | HC Wainwright & Co.Raghuram Selvaraju |
Reiterates | Buy | $10 |
| 2024-04-04 | HC Wainwright & Co.Raghuram Selvaraju |
Reiterates | Buy | $10 |
| 2024-03-20 | HC Wainwright & Co.Raghuram Selvaraju |
Reiterates | Buy | $10 |
| 2024-01-03 | HC Wainwright & Co.Raghuram Selvaraju |
Maintains | Buy | $12 → $10 |
| 2023-12-04 | HC Wainwright & Co.Raghuram Selvaraju |
Reiterates | Buy | $12 |
| 2023-10-04 | HC Wainwright & Co.Raghuram Selvaraju |
Reiterates | Buy | $12 |
| 2023-08-15 | HC Wainwright & Co.Raghuram Selvaraju |
Reiterates | Buy | $12 |
| 2023-08-11 | HC Wainwright & Co.Raghuram Selvaraju |
Reiterates | Buy | $12 |
| 2023-06-02 | HC Wainwright & Co.Raghuram Selvaraju |
Reiterates | Buy | $12 |
| 2023-05-24 | HC Wainwright & Co.Raghuram Selvaraju |
Maintains | Buy | $35 → $12 |
| 2023-01-24 | HC Wainwright & Co.Raghuram Selvaraju |
Maintains | Buy | $42 → $35 |
| 2022-11-07 | HC Wainwright & Co.Raghuram Selvaraju |
Maintains | Buy | $4 → $42 |
| 2020-11-12 | HC Wainwright & Co.Raghuram Selvaraju |
Maintains | Buy | $60 → $54 |
| 2020-07-08 | HC Wainwright & Co.Raghuram Selvaraju |
Initiates coverage on | Buy | $60 |
| 2020-06-16 | Noble Capital Markets |
Initiates coverage on | Outperform | $60 |
Ratings and price targets reflect each firm's most recent published action. Consensus combines the latest call from every covering firm over the past 12 months; price targets are typically 12-month horizons.
Key Stats
- Last Close
- $1.11
- Market Cap
- $22.15 million
- 52-Week Range
- $0.76 – $2.67
- Average Volume
- 67K shs
Data is delayed and provided for informational purposes only. Not investment advice. See our disclaimer.